bioRxivCancer Biology
PTEN loss in glioma cell lines leads to increased extracellular vesicle biogenesis and PD-L1 cargo in a PI3K-dependent manner
J. C. Sanchez, T. M. Pierpont, D. Argueta-Zamora, K. F. Wilson, A. August, R. A. Cerione
Abstract
Phosphatase and Tensin Homologue (PTEN) is one of the most frequently lost tumor suppressors in cancer and the predominant negative regulator of the PI3K/AKT signaling axis. A growing body of evidence has highlighted the loss of PTEN with immuno-modulatory functions including the upregulation of the programmed death ligand-1 (PD-L1), an altered tumor derived secretome that drives an immunosuppressive tumor immune microenvironment (TIME), and resistance to certain immunotherapies. Given their roles in immunosuppression and tumor growth, we examined whether the loss of PTEN would impact the biogenesis, cargo, and function of extracellular vesicles (EVs) in the context of the anti-tumor associated cytokine interferon-{gamma} (IFN-{gamma}). Through genetic and pharmacological approaches, we show that PD-L1 expression is regulated by JAK/STAT signaling, not PI3K signaling. Instead, we observe that PTEN loss positively upregulates cell surface levels of PD-L1 and enhances the biogenesis of EVs enriched with PD-L1 in a PI3K-dependent manner. We demonstrate that because of these changes, EVs derived from glioma cells lacking PTEN have a greater ability to suppress T cell receptor (TCR) signaling. Taken together, these findings provide important new insights into how the loss of PTEN can contribute to an immunosuppressive TIME, facilitate immune evasion, and highlight a novel role for PI3K signaling in the regulation of EV biogenesis and the cargo they contain.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: cell type annotation
- research focus: cell-cell communication
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of the tumor suppressor PTEN activates cell-intrinsic interferon signaling to drive immune resistance
Yubao Wang, Cherubin Manokaran, … Thomas M. Roberts·bioRxiv·Sep 17, 2025
- Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer
Ikjot Singh Sohal, Sydney N. Shaw, … Andrea L. Kasinski·bioRxiv·May 13, 2026
- The Necroptosis Effector MLKL drives Small Extracellular Vesicle Release and Tumour Growth in Glioblastoma
G. Andre-Gregoire, T. Douanne, … J. Gavard·bioRxiv·Jan 12, 2021
- EGFL7 promotes immune evasion in glioblastoma by interaction with integrin β2
Sukrit Mahajan, Philipp Abe, … Mirko H. H. Schmidt·bioRxiv·Jul 28, 2025
- Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells
Y. Shi, M. Dolan, … J. M. L. Ebos·bioRxiv·Jul 1, 2021
- Bidirectional crosstalk between epithelial-mesenchymal plasticity and IFNγ-induced PD-L1 expression promotes tumor progression
Gerhard A. Burger, Daphne Nesenberend, … Joost B. Beltman·Royal Society Open SciencePeer-reviewed·Nov 1, 2022